Galecto, Inc. (GLTO)
| Market Cap | 46.23M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -55.35M |
| Shares Out | 25.26M |
| EPS (ttm) | -2.19 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13,477 |
| Open | 1.83 |
| Previous Close | 1.80 |
| Day's Range | 1.83 - 1.87 |
| 52-Week Range | 1.17 - 5.47 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 10.97 (+499.5%) |
| Earnings Date | Aug 4, 2022 |
About GLTO
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 i... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for GLTO stock is "Buy." The 12-month stock price forecast is 10.97, which is an increase of 499.45% from the latest price.
News
Galecto to Participate at Jefferies Healthcare Conference
BOSTON, May 31, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced that...
Galecto to Present New Data on Oral Galectin-3 Inhibitor GB1211 at the 2022 ASCO Annual Meeting
Novel galectin-3-based mechanism of PD-1/PD-L1 checkpoint inhibitor resistance identified
Galecto Reports First Quarter Operating and Financial Results
BOSTON, April 29, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced it...
Galecto Completes Enrollment in Global Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of IPF
GB0139 is Galecto's proprietary inhaled once-daily small molecule galectin-3 inhibitor
Galecto Completes Enrollment in Phase 1b/2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Li...
Top-line results from GULLIVER-2 trial on track for the fourth quarter of 2022
Galecto, Inc. (GLTO) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Galecto, Inc. (GLTO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a...
Galecto Reports Financial Results for the Year Ended December 31, 2021
Continued pipeline progress with three potentially first-in-class product candidates
Galecto Publishes Results Showing Safety and Efficacy of the GB0139 Inhaled Galectin-3 Inhibitor in Hospitalized COVI...
Results Support Favorable Safety and Tolerability Profile and Target Engagement of GB0139 and Potential for GB0139 in Severe Lung Disease
Galecto Announces Positive Preliminary Results for Oral Galectin-3 Inhibitor GB1211 in Part 1 of its Phase 1b/2a Live...
GB1211 observed to be safe and well tolerated in initial twelve randomized subjects, including six hepatically impaired liver cirrhosis patients
Galecto Reports Third Quarter Operating and Financial Results
Announces clinical collaboration with Roche for first line NSCLC
Galecto To Test GB1211 Combined with Roche's Tecentriq In First Line Lung Cancer Setting
Galecto Inc (NASDAQ: GLTO) has entered into a clinical trial supply agreement with Roche Holdings AG (OTC: RHHBY) to explore the combination of GB1211 in a planned Phase 2a trial in non-small-cell lung ...
Galecto Announces Clinical Collaboration with Roche for Phase 2 Trial of GB1211 in Combination with Atezolizumab in F...
Upcoming Phase 2 trial marks expansion of Galecto pipeline into oncology and provides opportunity for exploring the use of galectin-3 inhibitors in cancer
Galecto to Present at Upcoming Investor Conferences
BOSTON, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced tha...
Galecto to Present at 2021 Cantor Virtual Global Healthcare Conference
BOSTON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced th...
Galecto Announces First Patient Treated in Phase 2 Trial of Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis
Galecto now has three ongoing Phase 2 clinical trials with three different drug candidates in three high value indications Galecto now has three ongoing Phase 2 clinical trials with three different drug...
Galecto Starts Dosing In Mid-Stage Myelofibrosis Trial
Galecto Inc (NASDAQ: GLTO) has announced the treatment of the first patient in a Phase 2a trial of its oral LOXL2 inhibitor GB2064 in myelofibrosis. Myelofibrosis, a form of chronic leukemia, is a rare...
Galecto Announces First Patient Treated in Phase 2a Trial of the Oral LOXL2 Inhibitor GB2064 in Myelofibrosis (the MY...
BOSTON, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced the treatment of t...
Galecto Reports Second Quarter Operating and Financial Results
BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced its...
3 Net Current Asset Value Stock Picks
There are some investors who invest in U.S.-listed stocks that are trading below their liquidation values because they believe they can make huge margins of return out of these stocks after the market h...
Galecto Resumes Recruitment in Phase 2b Global GALACTIC-1 Trial of GB0139 for Idiopathic Pulmonary Fibrosis
BOSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a publicly listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced th...
Galecto's GB0139 Shows Favorable Safety and Tolerability Profile with Promising Changes in Efficacy Markers in Hospit...
BOSTON and COPENHAGEN, Denmark, June 22, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a publicly listed, clinical stage biotechnology company focused on the development of novel treatments for...
Galecto Hosting Expert Perspectives Webinar on the Current Myelofibrosis Treatment Landscape and Potential Future Tre...
Webinar on Wednesday, June 9th @ 8amET Webinar on Wednesday, June 9th @ 8amET
Galecto Reports First Quarter Financial Results and Provides a Corporate Update
BOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced its ...
Galecto (GLTO) Enters Oversold Territory
Galecto (GLTO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
Galecto Reports Financial Results for the Year Ended December 31, 2020 and Provides a Corporate Update
BOSTON, March 29, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced it...